A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real-World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluation.

IF 6.3 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Shirley V Wang, Massimiliano Russo, Robert J Glynn, Marie C Bradley, Jiwei He, John Concato, Sebastian Schneeweiss
{"title":"A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real-World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluation.","authors":"Shirley V Wang, Massimiliano Russo, Robert J Glynn, Marie C Bradley, Jiwei He, John Concato, Sebastian Schneeweiss","doi":"10.1002/cpt.3621","DOIUrl":null,"url":null,"abstract":"<p><p>Real-world evidence involving healthcare database studies is well established for making causal inferences in post-market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. The rapidly expanding field of etiologic research using insurance claims and electronic health records databases is being evaluated for supporting effectiveness claims. One such use case to support regulatory decision-making on effectiveness is for expanding indications beyond existing effectiveness claims. Confidence in the validity of findings from cohort studies conducted using databases (hereafter \"database study\") to support indication expansions could be increased through a structured benchmarking process of an initial database study against RCT evidence followed by calibration of a subsequent database study based on differences in results observed in the initial RCT-database pair. This paper proposes a benchmark, expand, and calibration (BenchExCal) approach to trial emulation and describes the design and process for evaluating the performance of the approach through both simulation studies; five planned empirical examples are also described. The project will provide insights regarding how a first-stage benchmarking emulation of a completed trial for an existing indication can be used to calibrate, increase confidence, and improve interpretation of the results for a second-stage emulation of a hypothetical trial that could potentially provide evidence for an expanded indication. Although the examples have been selected to provide a variety of learnings, five use cases do not address all clinical and data scenarios that may be encountered when seeking a supplemental indication for a marketed drug.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cpt.3621","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Real-world evidence involving healthcare database studies is well established for making causal inferences in post-market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. The rapidly expanding field of etiologic research using insurance claims and electronic health records databases is being evaluated for supporting effectiveness claims. One such use case to support regulatory decision-making on effectiveness is for expanding indications beyond existing effectiveness claims. Confidence in the validity of findings from cohort studies conducted using databases (hereafter "database study") to support indication expansions could be increased through a structured benchmarking process of an initial database study against RCT evidence followed by calibration of a subsequent database study based on differences in results observed in the initial RCT-database pair. This paper proposes a benchmark, expand, and calibration (BenchExCal) approach to trial emulation and describes the design and process for evaluating the performance of the approach through both simulation studies; five planned empirical examples are also described. The project will provide insights regarding how a first-stage benchmarking emulation of a completed trial for an existing indication can be used to calibrate, increase confidence, and improve interpretation of the results for a second-stage emulation of a hypothetical trial that could potentially provide evidence for an expanded indication. Although the examples have been selected to provide a variety of learnings, five use cases do not address all clinical and data scenarios that may be encountered when seeking a supplemental indication for a marketed drug.

基准,扩展和校准(BenchExCal)试验仿真方法,用于使用真实世界的证据来支持指示扩展:设计和过程计划的经验评估。
涉及医疗数据库研究的真实世界证据已经很好地建立起来,可以在上市后药物安全性研究中进行因果推断,并且近年来评估有效性的方法、数据和研究基础设施都取得了进展。正在评估利用保险索赔和电子健康记录数据库进行病因学研究的迅速扩大领域,以支持有效性索赔。支持有效性监管决策的一个这样的用例是扩大现有有效性声明之外的适应症。使用数据库进行的队列研究(以下简称“数据库研究”)支持适应症扩展,可以通过对初始数据库研究与RCT证据进行结构化基准测试过程,然后根据初始RCT-数据库对中观察到的结果差异对后续数据库研究进行校准,从而增加对结果有效性的信心。本文提出了一种基准、扩展和校准(BenchExCal)方法来进行试验仿真,并描述了通过两种仿真研究来评估该方法性能的设计和过程;还描述了五个有计划的经验例子。该项目将提供有关如何使用已完成的现有适应症试验的第一阶段基准模拟来校准、增加信心和改进对第二阶段模拟的结果的解释的见解,该模拟可能为扩大的适应症提供证据。虽然选择这些例子是为了提供各种学习,但五个用例并不能解决在寻求已上市药物的补充适应症时可能遇到的所有临床和数据情况。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.70
自引率
7.50%
发文量
290
审稿时长
2 months
期刊介绍: Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信